324 results
CORRESP
BMY
Bristol-Myers Squibb Co.
31 Aug 10
Correspondence with SEC
12:00am
investigational compound or product projects in phase III and whose R&D expenditures are 10% or more of R&D expenses to be significant projects … comment. We do not believe that determination of significance is limited to the phase of the project or the amount of R&D expense incurred
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
4 Mar 11
Bristol-Myers Squibb Names Elliott Sigal, M.D., Ph.D., to
12:00am
joined Bristol-Myers Squibb in November 1997 as vice president of Applied Genomics. Since then he has served in critical leadership roles within R&D, including … approvals and the R&D organization filled the drug pipeline with an unprecedented number of mid- and late-stage assets, five of which could be approved
CORRESP
BMY
Bristol-Myers Squibb Co.
14 Oct 10
Correspondence with SEC
12:00am
with the Commission that is substantially similar to the following:
The Company manages its research and development (R&D) programs on a portfolio basis, investing … portfolio of R&D assets to ensure that there is an appropriate balance of early-stage and late-stage programs to support the future growth of the Company. We
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Apr 13
Departure of Directors or Certain Officers
12:00am
of our productive R&D team who, under Elliott’s leadership, has delivered our strong portfolio and pipeline. As our company embarks on the next phase … of pipeline execution, this is a natural time for Francis to lead our R&D team. Having worked closely with Francis since 2010 when I invited him to join
8-K
EX-99.2
BMY
Bristol-Myers Squibb Co.
29 Jul 04
Bristol-myers Squibb Announces Second Quarter and Six Months Sales and Earnings for 2004
12:00am
ConvaTec
Medical Imaging
Consumer Medicines
Expenses:
% of Sales
%Var.
COGS
SG&A
Adv. & Promo.
R&D
In-process R&D
Gain on sale of businesses
Provision …
Nutritionals
Other Healtcare
ConvaTec
Medical Imaging
Consumer Medicines
Expenses:
% of Sales
%Var.
COGS
SG&A
Adv. & Promo.
R&D
In-process R&D
Gain
CORRESP
eyllea18 jr
18 Jan 22
Correspondence with SEC
12:00am
425
a5se04yb6w6bylv
25 Mar 19
Business combination disclosure
5:25pm
8-K
EX-99.2
vj8ayi0x23rludflai4s
29 Jan 04
Financial statements and exhibits
12:00am
CORRESP
czlq1x umud
29 Jun 10
Correspondence with SEC
12:00am
8-K
EX-99.1
njim0n4icc
28 Apr 11
Key R&D Milestones and Strong Financials
12:00am
425
ru2ge3batmxokq
19 Mar 19
Business combination disclosure
7:04am
425
j5ks6k6 nhsz028y
31 Jan 19
Business combination disclosure
12:00am
UPLOAD
z230dq
16 Dec 21
Letter from SEC
12:00am
CORRESP
2lytwo1z1 7iv4
17 May 12
Correspondence with SEC
12:00am
DEFA14A
10ngu71xiz3x6c5k
8 Apr 13
Additional proxy soliciting materials
12:00am
8-K
EX-99.2
u84ta0j
28 Jul 05
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
pav8xu23
12 Oct 01
Acquisition or disposition of assets
12:00am
425
vzqe8z7
6 Mar 19
Business combination disclosure
7:03am